Protalix BioTherapeutics (PLX) Accumulated Expenses (2011 - 2026)

Protalix BioTherapeutics' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 175.33% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (up 175.33% YoY), while the FY2025 annual figure was $799000.0, down 55.88% from the prior year.
• Accumulated Expenses was $3.7 million for Q1 2026 at Protalix BioTherapeutics, up from $799000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $9.0 million in Q4 2023 to a low of $763000.0 in Q2 2025.
• Historically, Accumulated Expenses has averaged $3.7 million across 4 years, with a median of $1.8 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Accumulated Expenses sank 79.9% in 2024, then surged 175.33% in 2026.
• A 4-year view of Accumulated Expenses shows it stood at $9.0 million in 2023, then tumbled by 79.9% to $1.8 million in 2024, then plunged by 55.88% to $799000.0 in 2025, then jumped by 363.83% to $3.7 million in 2026.
• The last three Accumulated Expenses figures came in at $3.7 million (Q1 2026), $799000.0 (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.